Clinical Trial

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-12-21; most recent amendment 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2023-03-30
Trial Details
NCT Number NCT05669430
Lead Sponsor GV20 Therapeutics
Collaborators: Merck Sharp & Dohme LLC
Conditions Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Enrollment 365 participants
Start Date 2023-03-23
Primary Completion 2026-12-15 (estimated)
Study Completion 2027-09-05 (estimated)
Updated on ClinicalTrials.gov 2025-02-13